Cooper Companies ( (COO) ) has released its Q3 earnings. Here is a breakdown of the information Cooper Companies presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CooperCompanies, a global leader in the medical device industry, operates through its two main business units, CooperVision and CooperSurgical, focusing on contact lenses and women’s healthcare solutions, respectively. In its third quarter of 2025, CooperCompanies reported a 6% increase in revenue year-over-year, reaching $1,060.3 million. The company’s CooperVision unit saw a 6% rise in revenue, while CooperSurgical experienced a 4% increase. Despite a slight decrease in GAAP diluted earnings per share to $0.49, non-GAAP diluted EPS rose by 15% to $1.10, indicating strong operational performance. Key financial metrics highlighted include a gross margin of 65% and an operating margin of 17%, both slightly down from the previous year due to a product line exit at CooperSurgical. However, on a non-GAAP basis, the gross margin improved to 67%, and the operating margin rose to 26%, driven by efficiency gains and favorable foreign exchange impacts. The company also generated a robust free cash flow of $164.6 million. Looking ahead, CooperCompanies has raised its earnings guidance, anticipating improved revenue in the fourth quarter and fiscal year 2026, bolstered by the performance of its MyDAY® product line. The management remains confident in its strategy to deliver long-term shareholder value.